The exclusive patent license agreement with Sun Pharma is a significant financial event for Aclaris Therapeutics. The $15M upfront payment, along with potential milestone payments and royalties, is likely to have a positive impact on ACRS's revenue and could be viewed favorably by investors. This deal could also potentially enhance the company's pipeline and market presence, leading to a positive short-term impact on the stock price.